



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/689,513 10/21/2003		Michael L. Vazquez	101765.00016 (2751/5)	8659
22907	7590 11/15/2004		EXAMINER	
	& WITCOFF	SACKEY, EBENEZER O		
1001 G STR SUITE 1100		ART UNIT	PAPER NUMBER	
WASHINGT	ON, DC 20001	1626		
		DATE MAILED: 11/15/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)			
Office Action Summary		10/689,51	•	VAZQUEZ ET AL.			
		Examiner		Art Unit			
		EBENEZE	R SACKEY	1626			
Period fo	The MAILING DATE of this communication or Reply	appears on the	cover sheet with the c	orrespondence add	fress		
A SH THE - Exte after - If the - If NC - Faill Any	ORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CFI SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, a population of the period for reply secured above is less than thirty (30) days, a population of the period for reply within the set or extended period for reply will, by street or reply within the set or extended period for reply will, by street years and the period for reply will. Second than three months after the med patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event. a reply within the statured will apply and witatute, cause the appl	ent, however, may a reply be tim utory minimum of thirty (30) days Il expire SIX (6) MONTHS from ication to become ABANDONE	nely filed s will be considered timely, the mailing date of this cor	mmunication.		
Status							
1)⊠	Responsive to communication(s) filed on 2	25 August 2004					
	This action is FINAL . 2b)⊠ This action is non-final.						
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1 and 43-61 is/are pending in the 4a) Of the above claim(s) is/are with Claim(s) is/are allowed. Claim(s) 1 and 43-61 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and	drawn from cor					
Applicati	on Papers		,				
9)[The specification is objected to by the Exam	niner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to			• •			
11)	Replacement drawing sheet(s) including the cor The oath or declaration is objected to by the						
Priority L	ınder 35 U.S.C. § 119						
a)[Acknowledgment is made of a claim for fore All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International Bur see the attached detailed Office action for a	ents have beer ents have beer priority docume reau (PCT Rule	n received. n received in Application nts have been received e 17.2(a)).	on No d in this National S	stage		
Attachment	(s)						
1) Notice	e of References Cited (PTO-892)		4) Interview Summary (
3) 因 Inforn	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/ No(s)/Mail Date 10/21/03, 8/25/04.		Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	tei.	152)		

DETAILED ACTION

Status of Claims

Claims 1 and 43-61 are pending.

Preliminary Amendments

Receipt of the preliminary amendments filed 10/21/03 and 04/21/04 respectively is acknowledged and has been entered into the file.

Information Disclosure Statement

Receipt of the information disclosure statement filed 10/21/03, 04/21/04 and 08/25/04 respectively is acknowledged and has been entered into the file.

In reply to this office action, applicants should update the continuing data since serial number 10/138,534 has matured into patent number 6,683,648.

Specification

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Application/Control Number: 10/689,513

Art Unit: 1626

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1 and 43-61 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2, 5-11,17, 20-24, 26, 36-37, 40-41 of U.S.Patent number 6,022,872 and claims 1-2, 5-6, 9-10, 14, 17, 20, 26, 30, 36, 37 of U.S.Patent number 6,211,176. Although the conflicting claims are not identical, they are not patentably distinct from each other because there are substantial structural similarities to the compounds and compositions of formulae (I), (II), (III), (IV), thereof claimed in the patents which are parents of the instant case for treating same uses, i.e., retroviral infection as herein. Note R², in the instant claims while limited to benzyl is also embraced in the claims of the patents. See definition of R².

Art Unit: 1626

which can be aralkyl radicals. There is also identical or substantial overlap with remaining variables.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to E. Sackey whose telephone number is (703) 305-6889. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane, can be reached on (703) 308-4537. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

EOS

EMILY BERNHARDT PRIMARY EXAMINER GROUP ## 1 (arto

- Beinhard